Swiss Auto Components Stock News

Trade routes are being redrawn as BRICS countries push new supply chains, payment rails, and material corridors, and that ripple runs straight through the custody banks and FX specialists that keep money and securities moving. Investors watching those plumbing changes risk missing the story if they only track headlines. This article breaks down three stocks from our Global Custody Banks and FX/Risk-Management Providers screener that appear closely tied to these shifts, and explains how their...

Alcon stock reacts to UNITY M surgical microscope launch Alcon (SWX:ALC) just moved its UNITY platform forward with the commercial launch of UNITY M, a premium ophthalmic surgical microscope now rolling out in the U.S., Japan and other key markets. That product push comes as Alcon’s share price has been under pressure, with the stock at CHF55.0 and a 30-day share price return of down 9.36%. The 90-day share price return is up 4.72% and the 1-year total shareholder return is down 10.89%,...

In September 2026, European markets are navigating increased inflation concerns and rising bond yields, driven by geopolitical tensions and energy price surges. Amid this backdrop, growth companies with high insider ownership can offer a unique perspective on potential resilience and alignment of interests between management and shareholders.

Logitech International recently unveiled the MX Keypad for developers, a customizable AI-focused control center with GitHub Copilot, Claude Code, and OpenAI Codex integrations, plus three free months of GitHub Copilot Pro+ and a sustainability-focused design priced at $99.99/€99.99. The MX Keypad pushes Logitech International deeper into software-enabled peripherals by tying physical devices to AI agents, SDK-driven extensions, and a large existing installed base of compatible hardware. We...

Roche Holding (SWX:ROP) collaborator MediLink reported positive Phase III results for Tam-Peli in relapsed small-cell lung cancer. The Tam-Peli trial showed significant gains in overall survival and response rates for patients who had already relapsed after prior therapy. Genentech, Roche’s US biotech unit, received FDA Priority Review for Enspryng to treat MOGAD, a rare autoimmune disease with no approved therapies. The Tam-Peli Phase III success and Enspryng Priority Review sit alongside...

Medacta Group SA ( VTX:MOVE ) shareholders are probably feeling a little disappointed, since its shares fell 9.8% to...

Avolta (SWX:AVOL) just locked in extended contracts with Grupo Aeroportuario del Pacífico across four major Mexican airports, securing exposure to more than 30 million travelers a year and future store expansion opportunities. Avolta’s latest contract wins and its September 2026 blockchain payment pilot come against a mixed price backdrop, with the share price at CHF43.6 after a 30 day share price return down 12.31% and a 3 year total shareholder return of 22.61%, which points to longer term...

Novartis (SWX:NOVN) is under pressure after the Phase III HARBOR trial of delpacibart etedesiran in myotonic dystrophy type 1 missed its primary endpoint, a setback that triggered a sharp share price reaction. That disappointment landed on top of an already bruising week for Novartis, with the 7-day share price return down about 13.5% and the 30-day share price return lower by roughly 9.8% as investors reassessed pipeline risk after back-to-back late-stage trial failures. Yet over a longer...

UBS Group (SWX:UBSG) has just wrapped up a large debt tender program, agreeing to repurchase about $7.93b of outstanding notes after lifting its maximum purchase size to roughly $5.85b in total consideration. UBS Group’s shares trade at CHF44.56 after a 1 day share price return of 1.39% and a 90 day share price return of 14.55%. The 1 year total shareholder return of 41.25% and 5 year total shareholder return of 233.69% point to strong momentum that recent debt tender and issuance activity...

Avolta AG recently launched a pilot blockchain-based payment system that settles purchases directly with customers within seconds and, in a separate move, Dufry International AG extended agreements that keep Avolta operating and expanding across four major Mexican airports handling over 30 million passengers a year. The combination of faster in-store payments and secured, expanding footprints in long-standing Mexican airport partnerships tightens Avolta's grip on high-traffic travel hubs...

Logitech International (SWX:LOGN) drew fresh attention this week after shareholders approved amendments to the Articles of Incorporation at the 8 September 2026 AGM, putting the company’s governance framework in focus for investors. The share price has eased in recent months, with a 30-day share price return of down 4.9% and a 90-day share price return of down 8.9%, even as Logitech International rolled out the MX Keypad launch and new workplace research alongside the governance changes...

Barry Callebaut presented at Barclays' Global Consumer Staples Conference in Boston and outlined how a well supplied cocoa market supports its current risk management approach after recent weather and disease concerns in West Africa. The proposed 6% pay increase for Ghanaian cocoa farmers, combined with Ivory Coast's larger harvest, highlights how farmer incomes and regional crop quality can directly reshape Barry Callebaut's sourcing costs and supply security. This article will examine how...

Romande Energie Holding reported first half 2026 revenue of CHF 407.16 million and net income of CHF 46.4 million, alongside higher electricity and thermal generation volumes compared with the prior year period. Construction of the 10 MW Les Muids wind farm in France adds to Romande Energie Holding's 240 MW gross renewable portfolio across 14 operating assets and several projects under development. The combination of stronger first half profitability and the new Les Muids wind farm under...

UBS Group has delivered a very strong 5 year share price gain, yet current valuation checks still suggest the stock trades at a discount to what its fundamentals might justify. The Excess Returns intrinsic value estimate and market multiple view both lean toward undervaluation, even after this extended run. Over the past 5 years, UBS Group has returned about 226%, which puts pressure on any argument that it remains an obvious bargain without further analysis. Recent moves such as expanding...

Recent earnings event and what changed in the EMS-CHEMIE HOLDING story EMS-CHEMIE HOLDING (SWX:EMSN) just reported half year 2026 results, with sales at CHF 1,010.06 million versus CHF 1,019.59 million a year earlier, while net income reached CHF 258.29 million and earnings per share rose to CHF 11.04. That mix of slightly softer sales and higher profitability provides a clearer view of how the business is managing costs and pricing, which helps frame any assessment of the recent share...

In September 2026, European markets have faced challenges due to rising energy prices and inflation concerns, with the STOXX Europe 600 Index experiencing a decline. Despite these pressures, opportunities may exist for discerning investors seeking undervalued stocks that could potentially benefit from stabilizing conditions and technological advancements.

Novartis has delivered a strong 81.1% gain over the past five years, yet its current valuation checks still lean cheap. That puts fresh pressure on investors to judge whether the recent pullback is an opening or a warning. After a sharp 15.0% decline over the last week and an 11.9% slide over the past month, the stock looks out of step with its longer term track record. Over five years, Novartis has returned 81.1%, which points to meaningful long run value creation despite short term...

Geopolitics is heating up, central banks are keeping rates higher for longer, and UBS is openly warning that investors may be too relaxed about future volatility. That mix is reshaping how wealthy families use global wealth managers and private banks. If you care about where high net worth money goes when risk feels underpriced, you will want to see which 3 stocks in this screener are most exposed to this shift. The three stocks in this article are only a starter sample, since the full screen...

The analysts covering Swiss Life Holding AG ( VTX:SLHN ) delivered a dose of negativity to shareholders today, by...

Medacta Group shares closed at CHF118 after a tough run, with the stock down around 12% over the past three months. The market looks tired. The earnings release tells a different story. H1 2026 revenue reached €368.2m with net income of €41.9m, and management kept full year guidance and mid term targets intact. That combination of pressure on recent returns and reaffirmed growth ambitions is what matters for long term holders who care more about the next five years than the next five...

BioVersys stock closed at CHF27.40 after a choppy few weeks, with the share price down about 3% over seven days despite a slightly positive three month run. Traders reacted to a familiar biotech story, with heavy investment in trials, rising research spend and another half year loss of CHF15.6 million. The near term numbers look bruising. The longer view depends on whether a CHF69.3 million cash pile and an antibiotics and tuberculosis pipeline can carry the business through several more...

Partners Group Holding reported H1 2026 figures on 1 September 2026, with revenue of CHF 1,120.7 million and net income of CHF 502.1 million, both lower than the prior year period, and basic EPS from continuing operations of CHF 19.49. The combination of softer revenue and reduced earnings per share highlights pressure on the fee engine that underpins Partners Group Holding’s private markets platform. We will now look at how Partners Group Holding’s softer half year revenue shapes the...

UBS Group launched nine concurrent tender offers in early September 2026 to repurchase senior notes originally issued by Credit Suisse, while also expanding its U.S. wealth management bench with experienced advisors in key markets like Los Angeles, Atlanta and Bethesda. The bank’s decision to actively manage funding costs through the note buybacks, together with a higher Federal Reserve rate outlook, highlights how UBS is aligning its balance sheet and advisory franchise with a stickier...

EMS-CHEMIE HOLDING reported half-year 2026 results with sales of CHF 1,010.06 million, net income of CHF 258.29 million and basic earnings per share from continuing operations of CHF 11.04. Profit per share rose compared with the prior year while sales were slightly lower, which may point to tighter cost control or a richer product mix supporting stronger profitability. With profitability improving even as sales eased, investors may monitor how this develops within EMS-CHEMIE HOLDING's...